National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
NCT02664935
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
01214147611
Adult Trials: 18+ Years
- Prior anti-cancer treatment:
- Patients who refuse any standard of care first line therapy, are eligible to receive National Lung Matrix Trial treatment as first line therapy, providing they explicitly consent to this effect.
- Patients who have previously consented to and received standard of care first line therapy must have completed all standard of care therapy that the treating oncologist thinks is appropriate. As a minimum patients must have failed one or more lines of treatment (either radiological documentation of disease progression or due to toxicity). Patients whose disease has increased in size but is not classed as progressive disease as per RECIST criteria, will be eligible. Patients with no change at all in dimension of disease (i.e. true stability) after first line therapy will not be eligible.
- Patients who have progressed after surgical resection and adjuvant therapy will be eligible for entry without the need for the administration of first line metastatic therapy.
- Patients will also be eligible without the necessity for first line regimen if they have relapsed within 6 months of completion of definitive chemoradiation.
- Consented and provided an adequate specimen to adequately characterise the molecular genotype of the tumour in the molecular pre-screening according to the molecular exclusion rules (see Section 6.4 for definition of an adequate sample).
- Histological or cytologically confirmed NSCLC stage III (not suitable for radical radiotherapy or surgery) or stage IV. This includes patients who may have abnormal histology, but IHC strongly support either squamous cell carcinoma (p63 positivity) or adenocarcinoma (Thyroid transcription factor 1 [TTF1] positivity). If a physician and pathologist are convinced after multi-disciplinary review that the patient has stage III or IV NSCLC but where all the IHC is negative and the morphology does not distinguish a specific sub-type, these patients will be eligible for non-histology specific cohorts.
- CT or MRI scan of head, chest and abdomen within 28 days of treatment demonstrating measurable disease as per RECIST version 1.1 (see Appendix 1: Response Evaluation Criteria in Solid Tumours Version 1.1). (The same imaging modality must be used throughout treatment).
- Adequate haematological function within 7 days of treatment.
- Haemoglobin ≥ 90 g/L.
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.
- Platelets ≥ 100 x 109/L.
- Adequate hepatic function within 7 days of treatment in patients with no liver metastasis (see arm specific entry criteria for adequate hepatic function in patients with liver metastases).
- Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN). (Note that this will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of haemolysis or hepatic pathology), who may be allowed inclusion at the discretion of the local Investigator).
- Alanine transferase (ALT) ≤ 2.5 x ULN.
- Aspartate transferase (AST) ≤ 2.5 x ULN.
- Adequate renal function within 7 days of treatment.
- Creatinine clearance (CLcr) >50 ml/min (measured or calculated by Cockcroft and Gault equation - see Appendix 4: Cockcroft Gault Formula - Creatinine Clearance). If calculated CLcr is <50 ml/min a direct measurement of glomerular filtration rate (GFR) such as EDTA may be performed. If the value is >50 ml/min the patient is eligible.
- Age ≥ 18 years.
- Females must agree to use adequate contraceptive measures (as defined in Section 6.3), should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:
- Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments
- Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
- Women aged under 50 years old would be consider postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range for the institution.
- Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
- Major surgery (excluding placement of vascular access) within 4 weeks prior to
treatment.
- Nausea, vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease)
that would preclude adequate absorption.
- Any psychological, familial, sociological or geographical condition hampering protocol
compliance.
- Concurrent malignancies or invasive cancers diagnosed within past 3 years except for
adequately treated basal cell carcinoma of the skin and in situ carcinoma of the
uterine cervix.
- Judgement by the local Investigator that the patient should not participate in the
study if the patient is unlikely to comply with study procedures, restrictions and
requirements.
- Any unresolved toxicity of grade 2, 3 or 4 from previous treatment (excluding
alopecia) at Registration (see CTCAE - Appendix 3: Common Toxicity Criteria Gradings).
- Patients who have previous symptomatic brain metastases or spinal cord compression are
excluded unless they have had adequate treatment, no evidence of progression or
symptoms, and have had no requirement for steroid treatment in the previous 28 days
before commencement of trial treatment.
- Patients with asymptomatic brain metastases picked up at screening CT scan are not
excluded providing that in the view of the local Investigator they do not require
immediate radiotherapy or surgical intervention, and have had no requirement for
steroid treatment in the previous 28 days before commencement of trial treatment.
- As judged by the local Investigator, any evidence of severe or uncontrolled systemic
diseases, including active bleeding diatheses, or active infection including hepatitis
B, hepatitis C and human immunodeficiency virus. Screening for chronic conditions is
not required.
- Pregnant and lactating patients (patients of childbearing potential must have a
negative pregnancy test prior to registration).
Cardiac exclusion criteria, performance status and prior treatment washout periods are
detailed within the National Lung Matrix Trial arm-specific eligibility criteria.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Aberdeen,
- Glasgow,
- Maidstone,
- Wirral,
- Belfast,
- Birmingham,
- Birmingham,
- Bristol,
- Cambridge,
- Cardiff,
- Colchester,
- Edinburgh,
- Exeter,
- Leeds,
- Leicester,
- London,
- London,
- London,
- London,
- London,
- Manchester,
- Newcastle,
- Oxford,
- Sheffield,
- Southampton,
| Descriptive Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Brief Title ICMJE | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | ||||||||
| Official Title ICMJE | National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer | ||||||||
| Brief Summary | The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol. | ||||||||
| Detailed Description | The trial is primarily an enrichment putative biomarker design, including patients who are positive for at least one of the actionable targets included in the trial. Patients who are positive for just one putative biomarker will receive the experimental targeted drug specific for that putative biomarker. Putative biomarkers within each drug cohort have been chosen such that in the majority of cases it is not expected that patients will be positive for two or more putative biomarkers within the same drug. In the rare situation that patients are positive for two or more putative biomarkers relevant across different drugs, treatment will be allocated in accordance with the following strategy:
| ||||||||
| Study Type ICMJE | Interventional | ||||||||
| Study Phase ICMJE | Phase 2 | ||||||||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||||||
| Condition ICMJE |
| ||||||||
| Intervention ICMJE |
| ||||||||
| Study Arms ICMJE |
| ||||||||
| Publications * |
| ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||||
| Recruitment Information | |||||||||
| Recruitment Status ICMJE | Recruiting | ||||||||
| Estimated Enrollment ICMJE | 549 | ||||||||
| Original Estimated Enrollment ICMJE | 620 | ||||||||
| Estimated Study Completion Date ICMJE | October 2022 | ||||||||
| Estimated Primary Completion Date | October 2022 (Final data collection date for primary outcome measure) | ||||||||
| Eligibility Criteria ICMJE | Core inclusion and exclusion criteria are presented below. Additional inclusion/exclusion criteria apply to each arm and are presented in the relevant arm supplements of the protocol. Inclusion Criteria:
Exclusion Criteria:
Cardiac exclusion criteria, performance status and prior treatment washout periods are detailed within the National Lung Matrix Trial arm-specific eligibility criteria. | ||||||||
| Sex/Gender ICMJE |
| ||||||||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||||
| Accepts Healthy Volunteers ICMJE | No | ||||||||
| Contacts ICMJE |
| ||||||||
| Listed Location Countries ICMJE | United Kingdom | ||||||||
| Removed Location Countries | |||||||||
| Administrative Information | |||||||||
| NCT Number ICMJE | NCT02664935 | ||||||||
| Other Study ID Numbers ICMJE | RG_14-072 2014-000814-73 ( EudraCT Number ) ISRCTN38344105 ( Other Identifier: ISRCTN Registry ) | ||||||||
| Has Data Monitoring Committee | Yes | ||||||||
| U.S. FDA-regulated Product | Not Provided | ||||||||
| IPD Sharing Statement ICMJE |
| ||||||||
| Responsible Party | University of Birmingham | ||||||||
| Study Sponsor ICMJE | University of Birmingham | ||||||||
| Collaborators ICMJE |
| ||||||||
| Investigators ICMJE |
| ||||||||
| PRS Account | University of Birmingham | ||||||||
| Verification Date | January 2021 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | |||||||||